December 16, 2021 4:59pm

Remember, Quadruple Witching is tomorrow, when options and futures on indexes and equities expire simultaneously

As I stated this a.m., “When I see a peak, I’d be selling upside with positive aftermarket indications.”

Pre-open indication results: 5 HITs, 3 MISS

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.


The Dow closed DOWN -29.79 points (-0.08%); the S&P closed DOWN -41.18 points (-0.87%) while the Nasdaq closed DOWN -385.15 points (-2.47%)

 

Henry’omics:

Indexes were down as the Dow as the S&P and Nasdaq dived the most on Thursday trading following the Fed’s shift toward ending its pandemic era policies early next year.

 

Economic data Docket: weekly jobless claims came in slightly higher than expected, while housing starts for November were much stronger than economists projected after declining in the prior month.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Thursday opened positive at 20 ups/13 downs, 1 flat and 1 acquired, flipped negative at the mid-day at 9/2, 1 flat and 1 acquired, ending with a negative close of 3 up/30 downs, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “once upon a bounce, comes a trounce? When I see a peak, I’d be selling upside with positive aftermarket indications.” …  https://www.regmedinvestors.com/articles/12229

 

Pre-open indication results: 5 HITs: <Biostage (OTCQB: BSTG), Fate Therapeutics (FATE -$3.04), Global Blood Therapeutics (GBT -$0.55), Intellia Therapeutics (NTLA -$7.68), CRISPR Therapeutics (CRSP -$2.41)> and 3 MISS: < Mesoblast (MESO -$0.01), uniQure N.V. (QURE -$8.51), Solid Biosciences (SLDB +$0.03)>

 

Key Metric - volume

Sector volume LOW with 1 of the 3-upside having higher than the 3-month average volume with INCREASED volume of 13 of 30-downside having higher than the 3-month average volume;

 

Note: Biostage (BSTG) closed flat on Thursday with 371 shares traded after Wednesday’s flat with 3,281 shares traded after Tuesday’s flat with 500 shares traded after Monday’s 0 shares traded; WHEN will or has he, David Green, the new interim CEO and chairman STOPPED the “pump and promote”?

 

Jumping with share pricing momentum (10 of xx):

  • AxoGen (AXGN +$0.06 after Wednesday’s -$0.05),
  • Solid Biosciences (SLDB +$0.03),
  • Bellicum Pharmaceuticals (BLCM +$0.01),

Hammered in today’s market (10 of 30):

  • uniQure NV (QURE -$8.51 after Wednesday’s -$9.07),
  • Intellia Therapeutics (NTLA -$7.68 after Wednesday’s +$7.03 and Tuesday’s +$1.02),
  • Alnylam Pharmaceuticals (ALNY -$6.18 after Wednesday’s +$5.33, Tuesday’s -$0.69 and Monday’s +$12.77),
  • Ultragenyx (RARE -$3.10 after Wednesday’s +$1.30, Tuesday’s +$2.12 and Monday’s +$1.73),
  • Fate Therapeutics (FATE -$3.04 after Wednesday’s +$4.50, Tuesday’s +$1.19 and Monday’s -$0.18),
  • CRISPR Therapeutics (CRSP -$2.41 after Wednesday’s +$4.28, Tuesday’s +$1.59 and Monday’s -$0.63),
  • Regenxbio (RGNX -$2.19),
  • Editas Medicine (EDIT -$2.11 after Wednesday’s +$1.32, Tuesday’s -$0.64 and Monday’s +$0.25),
  • BioLife Solutions (BLFS -$1.76 after Wednesday’s +$1.62, Tuesday’s -$1.49),
  • ReNeuron (RENE.L -$1.50 after Wednesday’s -$4.00, Tuesday’s -$5.50 and Monday’s -$1.50),

Closing Flat:

  • 1 – Biostage (BSTG) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed down -0.99% and XBI closed down -2.61%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +1.28 points or +6.64% at 20.57

 

December, the second month of Q4/21:

Thursday closed negative with 3 incliners, 30 decliners, 1 flat and 1 acquired

Wednesday closed positive with 27 incliners, 6 decliners 1 flat and 1 acquired

Tuesday closed negative with 7 incliners, 27 decliners and 1 acquired

Monday (12/13) closed positive with 16 incliner, 15 decliners, 3 flats and 1 acquired

 

 

The BOTTOM LINE: Sector stocks Thursday spilled to the downside, having popped to the upside on Wednesday after being sold-off Tuesday, came back to the upside.

Volume was moderately higher in the sector versus Wednesday and Tuesday.

  • Today - Sector volume LOW with 1 of the 3-upside having higher than the 3-month average volume with INCREASED volume of 13 of 30-downside having higher than the 3-month average volume;
  • Wednesday - Sector volume INCREASED with 12 of the 27-upside having higher than the 3-month average volume with INCREASED volume of 5 of 6-downside having higher than the 3-month average volume;
  • Tuesday - Sector volume INCREASED with 5 of the 7-upside having higher than the 3-month average volume with INCREASED volume of 13 of 27-downside having higher than the 3-month average volume;
  • Monday - Sector volume INCREASED with 8 of the 16-upside having higher than the 3-month average volume with INCREASED volume of 9 of 15-downside having higher than the 3-month average volume;

Thursday’s trading action was marked by struggles for many sector equities with AxoGen (AXGN) thinly popping along with the few upsiders, Solid Biosciences (SLDB) and Bellicum Pharmaceuticals (BLCM).

Despite gains for the sector last week, direction is still unclear. But historically, December has been a strong month for the stock market.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.